

# Giovanni Blandino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5731538/publications.pdf>

Version: 2024-02-01

212  
papers

12,849  
citations

23567

58  
h-index

28297

105  
g-index

215  
all docs

215  
docs citations

215  
times ranked

16266  
citing authors

#	ARTICLE	IF	CITATIONS
1	CircPVT1: a pivotal circular node intersecting Long Non-Coding-PVT1 and c-MYC oncogenic signals. <i>Molecular Cancer</i> , 2022, 21, 33.	19.2	23
2	Evidence of a SARS-CoV-2 double Spike mutation D614G/S939F potentially affecting immune response of infected subjects. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 733-744.	4.1	6
3	Long Non-Coding RNAs in the Cell Fate Determination of Neoplastic Thymic Epithelial Cells. <i>Frontiers in Immunology</i> , 2022, 13, 867181.	4.8	1
4	Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. <i>Nature Communications</i> , 2022, 13, 2800.	12.8	21
5	MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. <i>Communications Biology</i> , 2022, 5, .	4.4	8
6	YAP and TAZ: Monocorial and bicorial transcriptional co-activators in human cancers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188756.	7.4	9
7	YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer. <i>Cancer Letters</i> , 2021, 500, 51-63.	7.2	54
8	Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. <i>Cell Death and Differentiation</i> , 2021, 28, 1493-1511.	11.2	19
9	Two distinct TP53 mutations in HNSCC primary tumor: Only one circulates in the blood. <i>Oral Oncology</i> , 2021, 115, 105096.	1.5	1
10	MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies. <i>Translational Cancer Research</i> , 2021, 10, 3090-3110.	1.0	15
11	YAP and endothelin-1 signaling: an emerging alliance in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 27.	8.6	23
12	CircRNAs: role in human diseases and potential use as biomarkers. <i>Cell Death and Disease</i> , 2021, 12, 468.	6.3	191
13	Drugging the Master Regulator TP53 in Cancer: Mission Possible?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1595-1597.	1.6	5
14	H-Ras gene takes part to the host immune response to COVID-19. <i>Cell Death Discovery</i> , 2021, 7, 158.	4.7	11
15	METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors. <i>Clinical Epigenetics</i> , 2021, 13, 173.	4.1	21
16	Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. <i>Cell Death and Disease</i> , 2021, 12, 1019.	6.3	3
17	Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 344.	8.6	9
18	Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes a Prognostic Signature. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12071.	4.1	7

#	ARTICLE	IF	CITATIONS
19	Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 105-117.	5.0	33
20	Oral mucositis: the hidden side of cancer therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 210.	8.6	146
21	Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research Purposes. <i>Frontiers in Oncology</i> , 2020, 10, 922.	2.8	1
22	Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer. <i>Communications Biology</i> , 2020, 3, 677.	4.4	13
23	Metformin: Metabolic Rewiring Faces Tumor Heterogeneity. <i>Cells</i> , 2020, 9, 2439.	4.1	22
24	LINC00174 is a novel prognostic factor in thymic epithelial tumors involved in cell migration and lipid metabolism. <i>Cell Death and Disease</i> , 2020, 11, 959.	6.3	27
25	A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 4145-4157.	0.9	38
26	BRAF status modulates Interleukin-8 expression through a CHOP-dependent mechanism in colorectal cancer. <i>Communications Biology</i> , 2020, 3, 546.	4.4	8
27	Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. <i>Cancer Letters</i> , 2020, 492, 84-95.	7.2	12
28	TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 200.	8.6	25
29	Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5616-5630.	5.2	10
30	Circular RNAs in Embryogenesis and Cell Differentiation With a Focus on Cancer Development. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 389.	3.7	22
31	microRNA-378a-5p is a novel positive regulator of melanoma progression. <i>Oncogenesis</i> , 2020, 9, 22.	4.9	30
32	Arenavirus as a potential etiological agent of odontogenic tumours in humans. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 34.	8.6	3
33	Paracrine Signaling from Breast Cancer Cells Causes Activation of ID4 Expression in Tumor-Associated Macrophages. <i>Cells</i> , 2020, 9, 418.	4.1	10
34	Cancer at the time of the COVID-19 hurricane. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 74.	8.6	8
35	Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 257.	3.7	15
36	PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2956-2971.	7.0	33

#	ARTICLE	IF	CITATIONS
37	Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 349.	8.6	13
38	Î <sup>2</sup> -arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. <i>Nature Communications</i> , 2019, 10, 3196.	12.8	40
39	The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2019, 11, 1347.	3.7	31
40	<sc>cTAZ</sc> : a safeguard factor of antiviral response. <i>EMBO Reports</i> , 2019, 20, .	4.5	0
41	In vivo experimental models account for higher complexity than in vitro preclinical settings in cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, S461-S464.	1.4	1
42	miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 141.	8.6	55
43	The circ<sc>RNA</sc>â€œmicro<sc>RNA</sc> code: emerging implications for cancer diagnosis and treatment. <i>Molecular Oncology</i> , 2019, 13, 669-680.	4.6	300
44	Argonaute 2 drives miR-145-5p-dependent gene expression program in breast cancer cells. <i>Cell Death and Disease</i> , 2019, 10, 17.	6.3	28
45	Circular RNA YAP1: a new player in gastric cancer. <i>Translational Cancer Research</i> , 2019, 8, S195-S197.	1.0	0
46	hMENA is a key regulator in endothelin-1/Î <sup>2</sup> -arrestin1â€œinduced invadopodial function and metastatic process. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3132-3137.	7.1	21
47	Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 627-635.	2.5	91
48	MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrnone and Diet in the ETiology of breast cancer prospective study. <i>Carcinogenesis</i> , 2018, 39, 98-108.	2.8	29
49	Cheâ€œ1 is targeted by câ€œMyc to sustain proliferation in preâ€œBâ€œcell acute lymphoblastic leukemia. <i>EMBO Reports</i> , 2018, 19, .	4.5	23
50	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , 2018, 33, 244-258.e10.	16.8	270
51	MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration. <i>Carcinogenesis</i> , 2018, 39, 293-304.	2.8	32
52	Zebrafish as experimental model to establish the contribution of mutant p53 and ID4 to breast cancer angiogenesis in vivo. <i>Journal of Thoracic Disease</i> , 2018, 10, E231-E233.	1.4	4
53	Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines. <i>Cancer Letters</i> , 2018, 433, 18-32.	7.2	20
54	Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages. <i>Breast Cancer Research</i> , 2018, 20, 59.	5.0	38

#	ARTICLE	IF	CITATIONS
55	Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma. <i>Theranostics</i> , 2018, 8, 1850-1868.	10.0	65
56	YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. <i>Cancers</i> , 2018, 10, 137.	3.7	89
57	New therapeutic strategies to treat human cancers expressing mutant p53 proteins. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 30.	8.6	160
58	Inhibitor of DNA Binding 4 (ID4). , 2018, , 2593-2600.		0
59	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , 2017, 7, 43013.	3.3	44
60	<sc>AMPK</sc> $\hat{2}1$ reduces tumor progression and improves survival in p53 null mice. <i>Molecular Oncology</i> , 2017, 11, 1143-1155.	4.6	28
61	MicroRNAs as Key Effectors in the p53 Network. <i>International Review of Cell and Molecular Biology</i> , 2017, 333, 51-90.	3.2	34
62	Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence. <i>Modern Pathology</i> , 2017, 30, 1387-1401.	5.5	44
63	The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. <i>EMBO Reports</i> , 2017, 18, 1331-1351.	4.5	78
64	Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. <i>Cell Discovery</i> , 2017, 3, 17022.	6.7	59
65	Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation. <i>Molecular Cancer</i> , 2017, 16, 88.	19.2	27
66	Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1 $\hat{2}$ stabilization. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 32.	8.6	23
67	<i>MCM7</i> and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. <i>Carcinogenesis</i> , 2017, 38, 64-75.	2.8	52
68	Melatonin and Hippo Pathway: Is There Existing Cross-Talk?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1913.	4.1	34
69	Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. <i>International Journal of Molecular Sciences</i> , 2017, 18, 961.	4.1	41
70	The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. <i>Genome Biology</i> , 2017, 18, 237.	8.8	179
71	MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer. <i>Oncotarget</i> , 2017, 8, 29540-29557.	1.8	26
72	Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells. <i>Oncotarget</i> , 2017, 8, 95674-95691.	1.8	33

#	ARTICLE	IF	CITATIONS
73	Genomic Instability: The Pivotal Role of Mutant P53 in Human Cancers. <i>Chemotherapy</i> , 2016, 05, .	0.0	0
74	Oncogenic Intra-p53 Family Member Interactions in Human Cancers. <i>Frontiers in Oncology</i> , 2016, 6, 77.	2.8	59
75	Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins. <i>Frontiers in Oncology</i> , 2016, 6, 170.	2.8	3
76	Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. <i>Molecular Oncology</i> , 2016, 10, 1008-1029.	4.6	115
77	Targeting TEAD/YAP-transcription-dependent necrosis, TRIAD, ameliorates Huntington's disease pathology. <i>Human Molecular Genetics</i> , 2016, 25, ddw303.	2.9	38
78	<sc>YAP</sc> enhances the pro-proliferative transcriptional activity of mutant p53 proteins. <i>EMBO Reports</i> , 2016, 17, 188-201.	4.5	154
79	MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E189-97.	2.0	45
80	Use of Buffy Coat miRNA Profiling for Breast Cancer Prediction in Healthy Women. <i>Methods in Molecular Biology</i> , 2016, 1379, 13-19.	0.9	4
81	microRNAs in Cancer Chemoprevention: Method to Isolate Them from Fresh Tissues. <i>Methods in Molecular Biology</i> , 2016, 1379, 21-29.	0.9	0
82	MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. <i>Seminars in Cell and Developmental Biology</i> , 2016, 50, 133-142.	5.0	27
83	Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. <i>Cancer Biology and Therapy</i> , 2016, 17, 79-82.	3.4	25
84	Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both?. <i>Aging</i> , 2016, 8, 1153-1155.	3.1	10
85	miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. <i>Oncotarget</i> , 2016, 7, 4009-4023.	1.8	49
86	Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. <i>Oncotarget</i> , 2016, 7, 20532-20548.	1.8	49
87	Inhibitor of DNA Binding 4 (ID4). , 2016, , 1-7.		0
88	Gain-of-Function p53. , 2016, , 1828-1831.		0
89	Cdx2 Polymorphism Affects the Activities of Vitamin D Receptor in Human Breast Cancer Cell Lines and Human Breast Carcinomas. <i>PLoS ONE</i> , 2015, 10, e0124894.	2.5	21
90	Oncogenic MicroRNAs: Key Players in Malignant Transformation. <i>Cancers</i> , 2015, 7, 2466-2485.	3.7	114

#	ARTICLE	IF	CITATIONS
91	Radioresistance in Head and Neck Squamous Cell Carcinoma – Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies. , 2015, , .		6
92	A STAT3-NFκB/DDIT3/CEBP $\beta$ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. <i>Oncotarget</i> , 2015, 6, 12637-12653.	1.8	65
93	EGF induces microRNAs that target suppressors of cell migration: miR-15b targets <i>MTSS1</i> in breast cancer. <i>Science Signaling</i> , 2015, 8, ra29.	3.6	57
94	Chemotherapy-induced inhibition of mTOR pathway enables stress-induced autophagy. <i>EMBO Journal</i> , 2015, 34, 1214-1230.	7.8	66
95	Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells <i>ex vivo</i> through inhibition of <i>de novo</i> lipogenesis. <i>Biochemical Journal</i> , 2015, 469, 177-187.	3.7	79
96	Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition. <i>RNA Biology</i> , 2015, 12, 690-700.	3.1	16
97	Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 89-100.	4.1	107
98	What biomarkers (if any) for precise medicine?. <i>Aging</i> , 2015, 7, 533-534.	3.1	4
99	Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. <i>Oncotarget</i> , 2015, 6, 5547-5566.	1.8	41
100	miR-181c associates with tumor relapse of high grade osteosarcoma. <i>Oncotarget</i> , 2015, 6, 13946-13961.	1.8	20
101	<i>Cynara scolymus</i> affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion. <i>Oncotarget</i> , 2015, 6, 18134-18150.	1.8	36
102	Epigenetic silencing of miR-145-5p contributes to brain metastasis. <i>Oncotarget</i> , 2015, 6, 35183-35201.	1.8	75
103	Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. <i>Oncotarget</i> , 2014, 5, 4129-4143.	1.8	40
104	Transcriptional Regulation by Mutant p53 and Oncogenesis. <i>Sub-Cellular Biochemistry</i> , 2014, 85, 91-103.	2.4	24
105	MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies. <i>Clinical Colorectal Cancer</i> , 2014, 13, 37-45.e4.	2.3	46
106	Tumor suppressor microRNAs: A novel non-coding alliance against cancer. <i>FEBS Letters</i> , 2014, 588, 2639-2652.	2.8	58
107	Interaction of mutant p53 with p73: A Surface Plasmon Resonance and Atomic Force Spectroscopy study. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 1958-1964.	2.4	15
108	Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. <i>Nature Medicine</i> , 2014, 20, 599-606.	30.7	250

#	ARTICLE	IF	CITATIONS
109	Downregulation of microRNAs 145-3p and 145-5p Is a Long-term Predictor of Postmenopausal Breast Cancer Risk: The ORDET Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2471-2481.	2.5	24
110	MicroRNAs: short non-coding players in cancer chemoresistance. <i>Molecular and Cellular Therapies</i> , 2014, 2, 16.	0.2	31
111	miR-155 Drives Telomere Fragility in Human Breast Cancer by Targeting TRF1. <i>Cancer Research</i> , 2014, 74, 4145-4156.	0.9	108
112	VDR primary targets by genome-wide transcriptional profiling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 348-356.	2.5	36
113	MicroRNA expression profiling of thymic epithelial tumors. <i>Lung Cancer</i> , 2014, 85, 197-204.	2.0	43
114	Tumor suppression. <i>FEBS Letters</i> , 2014, 588, 2557-2557.	2.8	0
115	microRNAs: short non-coding bullets of gain of function mutant p53 proteins. <i>Oncoscience</i> , 2014, 1, 427-433.	2.2	17
116	microRNAs and cancer metabolism reprogramming: the paradigm of metformin. <i>Annals of Translational Medicine</i> , 2014, 2, 58.	1.7	28
117	Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. <i>Breast Cancer Research</i> , 2013, 15, R46.	5.0	31
118	ChIP-on-chip to Identify Mutant p53 Targets. <i>Methods in Molecular Biology</i> , 2013, 962, 211-226.	0.9	4
119	YAP and p73: A Matter of Mutual Specificity in Tumor Suppression. , 2013, , 147-172.		3
120	MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. <i>Cell Cycle</i> , 2013, 12, 1823-1823.	2.6	5
121	Gender, mutant p53 and PML: A growing affaire in tumor suppression and oncogenesis. <i>Cell Cycle</i> , 2013, 12, 1824-1825.	2.6	7
122	Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. <i>Carcinogenesis</i> , 2013, 34, 1051-1061.	2.8	52
123	PML Surfs into HIPPO Tumor Suppressor Pathway. <i>Frontiers in Oncology</i> , 2013, 3, 36.	2.8	14
124	The locus of microRNA-10b. <i>Cell Cycle</i> , 2013, 12, 2371-2375.	2.6	37
125	Editorial: (Thematic Issue: MicroRNAs: Non Coding Pleiotropic Factors in Development, Cancer) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.2	12
126	Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention. <i>Metabolites</i> , 2013, 3, 1051-1075.	2.9	26



#	ARTICLE	IF	CITATIONS
127	MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate Cancer. <i>Cancer Discovery</i> , 2012, 2, 236-247.	9.4	82
128	Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells. <i>Cell Cycle</i> , 2012, 11, 132-140.	2.6	27
129	miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. <i>Cell Death and Disease</i> , 2012, 3, e423-e423.	6.3	160
130	Hippo and <i>rassf1a</i> Pathways: A Growing Affair. <i>Molecular Biology International</i> , 2012, 2012, 1-12.	1.7	26
131	miR-10b*, a master inhibitor of the cell cycle, is downregulated in human breast tumours. <i>EMBO Molecular Medicine</i> , 2012, 4, 1214-1229.	6.9	85
132	Molecular Genetics and Biology of Head and Neck Squamous Cell Carcinoma: Implications for Diagnosis, Prognosis and Treatment. , 2012, , .		5
133	SNPs in DNA repair or oxidative stress genes and late subcutaneous fibrosis in patients following single shot partial breast irradiation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 7.	8.6	17
134	MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. <i>Cell Death and Differentiation</i> , 2012, 19, 1038-1048.	11.2	136
135	Direct and delayed X-ray-induced DNA damage in male mouse germ cells. <i>Environmental and Molecular Mutagenesis</i> , 2012, 53, 429-439.	2.2	27
136	Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. <i>Nature Communications</i> , 2012, 3, 865.	12.8	198
137	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012, 90, 667-679.	3.9	54
138	Prospective study on the role of glucose metabolism in breast cancer occurrence. <i>International Journal of Cancer</i> , 2012, 130, 921-929.	5.1	78
139	ChIP-on-Chip Analysis of <i>In Vivo</i> Mutant p53 Binding To Selected Gene Promoters. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 305-312.	2.0	36
140	Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13710-13715.	7.1	141
141	PGC1 $\beta$ Confers Specificity to Metabolic Stress and p53-Dependent Transcription. <i>Molecular Cell</i> , 2011, 44, 515-516.	9.7	7
142	Dose and polymorphic genes <i>xrcc1</i> , <i>xrcc3</i> , <i>gst</i> play a role in the risk of developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. <i>BMC Cancer</i> , 2011, 11, 291.	2.6	14
143	Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. <i>Cell Cycle</i> , 2011, 10, 4330-4340.	2.6	74
144	Chromatin Dynamics of Gene Activation and Repression in Response to Interferon $\beta$ (IFN $\beta$ ) Reveal New Roles for Phosphorylated and Unphosphorylated Forms of the Transcription Factor STAT2. <i>Journal of Biological Chemistry</i> , 2011, 286, 20217-20227.	3.4	51

#	ARTICLE	IF	CITATIONS
145	Omics Underpins Novel Clues on VDR Chemoprevention Target in Breast Cancer. OMICS A Journal of Integrative Biology, 2011, 15, 337-346.	2.0	6
146	Allelic Expression Imbalance ofTP53Mutated and Polymorphic Alleles in Head and Neck Tumors. OMICS A Journal of Integrative Biology, 2011, 15, 375-381.	2.0	10
147	The Cancer-associated K351N Mutation Affects the Ubiquitination and the Translocation to Mitochondria of p53 Protein. Journal of Biological Chemistry, 2011, 286, 39693-39702.	3.4	21
148	Gain of Function p53. , 2011, , 1486-1489.		0
149	Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53. Cancer Cell, 2010, 17, 273-285.	16.8	228
150	Che-1 Promotes Tumor Cell Survival by Sustaining Mutant p53 Transcription and Inhibiting DNA Damage Response Activation. Cancer Cell, 2010, 18, 122-134.	16.8	45
151	p53: The pivot between cell cycle arrest and senescence. Cell Cycle, 2010, 9, 4266-4265.	2.6	14
152	<i>Id2</i>gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle, 2010, 9, 2464-2466.	2.6	12
153	Novel insights into the cytoplasmic functions of p53. Cell Cycle, 2010, 9, 2491-2501.	2.6	1
154	Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle, 2010, 9, 2950-2959.	2.6	86
155	Stability strengths oncogenic activity. Cell Cycle, 2010, 9, 1456-1465.	2.6	0
156	Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19479-19484.	7.1	23
157	EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors. Science Signaling, 2010, 3, ra43.	3.6	100
158	ID4: a new player in the cancer arena. Oncotarget, 2010, 1, 48-58.	1.8	36
159	ID4: a new player in the cancer arena. Oncotarget, 2010, 1, 48-58.	1.8	25
160	Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle, 2010, 9, 2878-87.	2.6	51
161	Negative Regulation of Î²4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression. Cancer Research, 2009, 69, 5978-5986.	0.9	48
162	Metformin, diet and breast cancer: An avenue for chemoprevention. Cell Cycle, 2009, 8, 2661-2661.	2.6	33

#	ARTICLE	IF	CITATIONS
163	Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53. <i>Cancer Research</i> , 2009, 69, 4818-4826.	0.9	76
164	p63 regulation by microRNAs. <i>Cell Cycle</i> , 2009, 8, 1466-1470.	2.6	6
165	Tetraploidy triggers mitochondria. <i>Cell Cycle</i> , 2009, 8, 1305-1307.	2.6	0
166	Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. <i>Cell Cycle</i> , 2009, 8, 3396-3405.	2.6	16
167	YAP: At the crossroad between transformation and tumor suppression. <i>Cell Cycle</i> , 2009, 8, 49-57.	2.6	99
168	The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 1086-1093.	8.2	182
169	Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 135.	8.6	16
170	The Hippo Tumor Suppressor Pathway: A Brainstorming Workshop "The Hippo Tumor Suppressor Pathway: A Brainstorming Workshop" sponsored mainly by the Regina Elena Cancer Center and the Nicola Foundation and held in Rome, Italy, on 22 and 23 April 2009.. <i>Science Signaling</i> , 2009, 2, mr6.	3.6	13
171	PML, YAP, and p73 Are Components of a Proapoptotic Autoregulatory Feedback Loop. <i>Molecular Cell</i> , 2008, 32, 803-814.	9.7	224
172	Mitosis poisons p53. <i>Cell Cycle</i> , 2008, 7, 3287-3291.	2.6	0
173	The disruption of the protein complex mutant p53/p73 increases selectively the response of tumor cells to anticancer drugs. <i>Cell Cycle</i> , 2008, 7, 3440-3447.	2.6	83
174	Reversible Dysfunction of Wild-Type p53 following Homeodomain-Interacting Protein Kinase-2 Knockdown. <i>Cancer Research</i> , 2008, 68, 3707-3714.	0.9	78
175	Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. <i>Current Genomics</i> , 2008, 9, 200-207.	1.6	20
176	Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. <i>Cell Cycle</i> , 2008, 7, 1870-1879.	2.6	81
177	Mutant p53 Enhances Nuclear Factor $\kappa$ B Activation by Tumor Necrosis Factor $\alpha$ in Cancer Cells. <i>Cancer Research</i> , 2007, 67, 2396-2401.	0.9	178
178	P73, P63 and Mutant P53: Members of Protein Complexes Floating in Cancer Cells. , 2007, , 223-232.		3
179	YAP1 Meets Tumor Suppression. <i>Molecular Cell</i> , 2007, 27, 863-864.	9.7	14
180	Mutant p53 proteins: Between loss and gain of function. <i>Head and Neck</i> , 2007, 29, 488-496.	2.0	45

#	ARTICLE	IF	CITATIONS
181	Mutant p53: an oncogenic transcription factor. <i>Oncogene</i> , 2007, 26, 2212-2219.	5.9	241
182	p73, p63 and Mutant p53: Members of Protein Complexes Floating in Cancer Cells. , 2007, , 223-232.		0
183	Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. <i>Cancer Cell</i> , 2006, 10, 191-202.	16.8	386
184	Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73. <i>Journal of Cell Biology</i> , 2006, 172, 589-604.	5.2	84
185	ÎEF1 repressor controls selectively p53 family members during differentiation. <i>Oncogene</i> , 2005, 24, 7273-7280.	5.9	42
186	A Role of p73 in Mitotic Exit. <i>Journal of Biological Chemistry</i> , 2005, 280, 30354-30360.	3.4	35
187	The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. <i>Molecular Cell</i> , 2005, 18, 447-459.	9.7	318
188	The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. <i>Molecular Cell</i> , 2005, 19, 429.	9.7	3
189	p73-induced apoptosis: A question of compartments and cooperation. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 688-693.	2.1	37
190	p73 and p63: Why Do We Still Need Them?. <i>Cell Cycle</i> , 2004, 3, 884-892.	2.6	52
191	HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. <i>Oncogene</i> , 2004, 23, 5185-5192.	5.9	60
192	Pin1 Links the Activities of c-Abl and p300 in Regulating p73 Function. <i>Molecular Cell</i> , 2004, 14, 625-636.	9.7	165
193	Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73. <i>Journal of Biological Chemistry</i> , 2003, 278, 10546-10555.	3.4	36
194	p73 Is Regulated by Phosphorylation at the G2/M Transition. <i>Journal of Biological Chemistry</i> , 2003, 278, 49196-49202.	3.4	37
195	p73-Mediated Chemosensitivity: A Preferential Target of Oncogenic Mutant p53. <i>Cell Cycle</i> , 2003, 2, 345-346.	2.6	34
196	p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53. <i>Cell Cycle</i> , 2003, 2, 348-9.	2.6	20
197	Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities. <i>Journal of Biological Chemistry</i> , 2002, 277, 18817-18826.	3.4	203
198	Identification of Direct p73 Target Genes Combining DNA Microarray and Chromatin Immunoprecipitation Analyses. <i>Journal of Biological Chemistry</i> , 2002, 277, 43359-43368.	3.4	125

#	ARTICLE	IF	CITATIONS
199	Expression of the $\beta 24$ integrin subunit induces monocytic differentiation of 32D/v-Abl cells. <i>Blood</i> , 2002, 100, 96-106.	1.4	45
200	DNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes. <i>Molecular Cell</i> , 2002, 9, 175-186.	9.7	298
201	Monoclonal antibodies raised against <i>Xenopus</i> p53 interact with human p73. <i>Oncogene</i> , 2002, 21, 1304-1308.	5.9	4
202	The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. <i>Nature</i> , 2002, 419, 853-857.	27.8	390
203	From p63 to p53 across p73. <i>FEBS Letters</i> , 2001, 490, 163-170.	2.8	79
204	Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity. <i>Journal of Biological Chemistry</i> , 2001, 276, 15164-15173.	3.4	368
205	The Transcriptional Repressor ZEB Regulates p73 Expression at the Crossroad between Proliferation and Differentiation. <i>Molecular and Cellular Biology</i> , 2001, 21, 8461-8470.	2.3	117
206	Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73. <i>Journal of Biological Chemistry</i> , 2000, 275, 29503-29512.	3.4	217
207	Interaction of c-Abl and p73 $\beta$ and their collaboration to induce apoptosis. <i>Nature</i> , 1999, 399, 809-813.	27.8	529
208	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. <i>Oncogene</i> , 1999, 18, 477-485.	5.9	411
209	Induced p21 <sup>waf</sup> expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. <i>Oncogene</i> , 1999, 18, 2643-2649.	5.9	126
210	Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. <i>Oncogene</i> , 1998, 17, 1923-1930.	5.9	98
211	Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. <i>Oncogene</i> , 1997, 15, 607-611.	5.9	5
212	Induction of Mdm2 and enhancement of cell survival by bFGF. <i>Oncogene</i> , 1997, 15, 2717-2725.	5.9	102